Micrologix biotech Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Micrologix biotech

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Graham Dellaire who wrote (25)	5/14/1997 9:42:00 PM
From: Dan Hamilton	of 792

News from MBI... Micrologix Biotech Inc - News Release Exclusive world-wide licence for production technology signed Micrologix Biotech Inc MBI Shares issued 23038599 1997-05-12 close $3.8 Tuesday May 13 1997 News Release Mr Dany Hadary reports, Micrologix Biotech Inc today announced the signing with the University of Victoria's Innovative and Development Corporation (IDC) of an exclusive world-wide licence for an enabling technology useful in the production of anti-infective peptides. The licence applies to discoveries made by scientists at Micrologix and the University of Victoria covering a unique method for increasing the efficiency of bacterial production of cationic antimicrobial peptides. Patents covering this technology are pending. Micrologix is one of a few companies in the field of peptide antibiotics that is developing a method for manufacturing peptide antibiotics using recombinant DNA technology in bacterial systems. Recombinant DNA technology offers a commercially viable, cost effective alternative to the current synthetic manufacturing technology for the production of peptides, especially complex peptides. The company recently announced the issuance of US Patent No. 5,593,866 covering its core recombinant DNA manufacturing technology. The acquisition of this enabling technology from IDC further strengthens Micrologix's capabilities to competitively produce and commercialize peptide-based antibiotic drugs. Micrologix Biotech Inc is a Canadian biopharmaceutical company dedicated to the discovery, development and commercialization of novel anti-infective drugs. The company's drug development program is based on proprietary technologies and extensive expertise in the molecular basis of microbial infections. (c) Copyright 1997 Canjex Publishing Ltd. canada-stockwatch.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next